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ABSTRACT 
Myocardial infarction (MI) leading eventually to heart failure is a major cause of morbidity 
and mortality in Western countries. Current studies suggest that cell-based therapies can 
improve cardiac function after MI. Paracrine factors mediated by transplanted cells have been 
suggested to be the curative factors behind this effect. 
In the present work, we evaluated preconditioning methods of skeletal myoblasts (SM) and 
bone marrow-derived mesenchymal stem cells (MSC) prior to transplantation in MI. We used 
epicardial transplantation of cell sheets in a rat model of MI which was induced by left 
anterior descending (LAD) coronary artery ligation. The preconditioning methods used were 
heat shock (HS) pre-treatment of SMs and gene modification of MSCs. Gene modification 
was performed by viral VEGF and Bcl-2 transductions. After preconditioning, cell sheets 
were transplanted onto MI and the therapeutic effect was evaluated. Furthermore, we studied 
the effect of HS pre-treatment on SM differentiation under hypoxic conditions and tested the 
hypothesis that HS preconditioning-treatment enhances the angiogenic properties of SM 
sheets. Metabolic activity of VEGF and Bcl-2 over-expressing cells was assessed under 
normal nutrient supply, serum starvation and staurosporine treatment.  
Our results demonstrate that HS preconditioning leads to increased expression of SM 
differentiation-associated troponin and to reduced caspase-3 activity from differentiation 
under hypoxic environment. HS-preconditioning protected SM sheets from hypoxia-
associated apoptosis in vitro; however it reduced vascular endothelial growth factor (VEGF) 
expression of the sheet, leading to a lower therapeutic effect in heart failure. MSC sheets 
carrying VEGF showed enhanced efficacy of cell sheet transplantation therapy in an acute 
infarction model. These cell sheets attenuated left ventricular dysfunction and myocardial 
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damage, and induced therapeutic angiogenesis. The metabolic activity of gene-over-
expressing cells was significantly higher compared to wild type cells. Moreover, introducing 
VEGF expression in MSCs enhanced the metabolic activity of cells during serum starvation 
and staurosporine treatment when compared to Bcl-2-expressing and wild type MSCs. 
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1. INTRODUCTION 
Despite the development of treatment methods, myocardial infarction (MI) and the resulting 
heart failure is still a major cause of morbidity and mortality in industrialised countries. 
Between 1% and 2% of the adult population in developed countries have heart failure, and it 
has become an increasingly important public health problem. The heart’s regenerative 
capacity is limited, and the main cause of heart failure caused by myocardial infarction is the 
permanent loss of contractile cells. Despite the modern reperfusion strategies and 
pharmacological management this leads to a progression to heart failure (Schachinger et al. 
2006; Perin & Silva 2011).  
Cell therapy is a promising therapeutic approach for treating the failing heart. Among the 
cells evaluated, MSCs and SMs are the most frequently studied in the patients with ischaemic 
heart disease. The autologous origin and high expansion potential allows prompt isolation 
and transplantation of these cells (Durrani et al. 2010). Transplantable cells face several 
damaging phases during and after the transplantation process, compromising their therapeutic 
effect. The choice of cell preconditioning has a significant role in enhancing the graft survival 
and the therapeutic effect of transplanted cells. It has been shown to increase the 
differentiation potency and paracrine activity of cells (Kubo et al. 2008).  
In the present study, we evaluated a HS preconditioning method of SMs in vitro and in vivo 
prior to myoblast sheet transplantation to an ischaemic heart. We also enhanced the 
therapeutic properties of mesenchymal stem cell (MSC) sheets by increasing their 
proangiogenic properties and evaluated the in vitro metabolic responses of proangiogenic 
vascular endothelial growth factor (VEGF) and anti-apoptotic Bcl-2 over-expressing MSCs 
under different in vitro stress conditions. 
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2. REVIEW OF THE LITERATURE 
2.1 Myocardial infarction and heart failure 
MI, more commonly known as heart attack, and the following heart failure are major causes 
of morbidity and mortality worldwide (Naresh et al. 2011; Flynn & O'Brien 2011). The main 
reason for MI is atherosclerosis, which blocks one or several of the coronary arteries and 
results in an imbalance in oxygen supply and demand. Prolonged ischaemia causes 
irreversible heart muscle loss. Myocardial cell death after MI releases mediators that alert the 
immune system and further promote cell death and tissue damage. These acute and chronic 
responses of MI have a significant role in the functional deterioration of the heart leading to 
systolic or diastolic heart failure (Arslan et al. 2011; Nadal-Ginard 2003; Pittenger et al. 
1999). 
The loss of ventricular muscle due to MI and the subsequent complex architectural 
modifications involving both the infarcted and non-infarcted myocardium contribute to the 
evolution of heart failure. Wall thinning and infarct expansion are the most important changes 
in the infarct region leading to both systolic (decreased contraction) and diastolic (decreased 
relaxation) dysfunction.  
Ironically, the development of treatment methods for acute myocardial infarction (AMI) has 
led to an increasing number of heart failure patients. If a patient survives the acute phase of 
MI, the heart enters left ventricular remodelling which is a part of the compensatory 
mechanism caused by the massive loss of healthy cardiomyocytes. Therefore, chronic disease 
management still continues to be a major challenge (Durrani et al. 2010). 
Therapeutic treatments of HF include pharmacotherapeutic alternatives, device therapies and 
cardiac surgical procedures. Angiotensin-converting enzyme inhibitors, β-blockers, diuretics 
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and angiotensin receptors blockers, cardiac resynchronisation therapy, implantable cardiac 
defibrillators and ventricular assist devices, coronary angioplasty and coronary artery bypass 
grafting (CABG) only help to save the reversibly-injured cells and restore contractility of the 
hibernating viable myocardium without solving the primary problem of myocyte loss 
(Haqqani and Mond 2009; Alba and Delgado 2009). The best treatment alternative at the 
moment for end-stage HF is heart transplantation. However, a major limitation of this option 
is the limited availability of donor hearts. Therefore, the development of new and efficient 
strategies for managing chronic heart disease and its related complications are warranted 
(Durrani et al. 2010). 
2.2 Cell therapy for heart failure 
The permanent loss of myocytes after MI and the theoretical regenerative capacity of heart 
have led to growing interest in cellular transplantation. An important goal of successful heart 
failure treatment would be to achieve widespread regeneration of myocardium and thus 
improve systolic function, as well as preventing or reversing the remodelling process (Dib et 
al. 2005; Shimizu et al. 2003; Hagege et al. 2006). For almost twenty years cell therapy 
research for the treatment of ischaemic heart disease, either alone or in combination with 
other therapeutic interventions, has shown an interesting alternative curative strategy (Leri et 
al. 2008; Heldman et al. 2011; Lee & Terracciano 2010).  
Many cell types have been studied in preclinical animal models and in clinical trials to either 
repair or regenerate the damaged myocardium either directly (through the formation of new 
transplanted tissue) or indirectly (through paracrine effects activating endogenous 
regeneration) (Murry et al. 2005; Gu et al. 2007; Malliaras & Marbán 2011). Different types 
of stem cell and progenitor cells from autologous or allogenic sources have been used for 
cardiac regeneration research (Hare & Chaparro 2008). Cell transplantation using embryonic 
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stem cells (Klug et al. 1996), foetal cardiomyocytes (Yokomuro et al. 2001), SMs (Rajnoch et 
al.2001), haematopoietic stem cells (Orlic et al. 2001), MSCs (Toma et al. 2002), and 
endothelial progenitor cells (Kawamoto et al. 2003), have emerged as a promising therapeutic 
approach for the restoration of heart functions after MI damage in experimental models, as 
well as in a clinical setting. 
One of the key issues in cell therapy is the use of autologous versus allogenic cells. Both cell 
sources have their advantages, however most clinical trials have used autologous cells to 
date. Autologous cells remain free of surface antigen-dependent rejection and provide a cell 
source that is free of donor-derived disease transmission. Disadvantages are, however, 
associated to the variance between patients, which makes the quality control and evaluation 
of the therapeutic potential of the cell products difficult (Menasché 2011). Also, the 
therapeutic efficacy of cells from elderly patients may be reduced (Li et al. 2010), and the 
lack of time makes the use of autologous cells unfeasible for treating acute MI. It takes time 
to harvest, culture and expand cells to the volume needed. The allogenic setting allows 
detailed characterisation and evaluation of the therapeutic potential of the cell product. The 
advantage of using high quality cells in large quantities and the possibility to manipulate the 
cells in advance is a very attractive possibility. However, immune reactions against 
transplanted cells demand strong suppressive medication, which is considered the major 
limitation of this approach.  
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Table 1. Characteristics of cell populations studied for heart cell therapy. (Modified from 
Gersh et al. 2009; Joggerst & Hatzopoulos 2009) 
Source Cell type Advantages Disadvantages 
Blood and bone 
marrow 
 
Haematopoietic stem 
cells; Endothelial 
progenitor cells; 
Mesenchymal stem 
cells; Multipotent adult 
progenitor cells 
 
Ease of access; 
Potential for 
vasculogenesis; 
Myocyte 
differentiation; Safe 
and feasible to implant 
Controversy over 
whether true 
cardiovascular 
differentiation takes 
place 
Umbilical cord-
derived cells 
 
Bone marrow 
mononuclear cells, 
haematopoietic stem 
cells, circulating 
progenitor cells  
 
Ease of access; High 
proliferation potential; 
Safe and feasible to 
implant 
Controversy over 
whether true 
cardiovascular 
differentiation takes 
place 
Skeletal muscle 
 
Myoblasts Ease of access, 
Extensive scalability, 
Resistance to 
ischaemia, 
Multipotent, No 
teratoma formation 
No electrical integration; 
Arrythmias; 
No transdifferentiation 
 
Blastocyst 
 
Embryonic stem cells 
 
Theoretically unlimited 
self-renewal capacity; 
Pluripotent 
Ethical considerations; 
Teratoma formation; 
Graft-versus-host disease 
Adipose tissue 
 
Endothelial progenitor 
cells, Mesenchymal 
stem cells, 
Ease of access; 
Multipotent;  Myocyte 
regenerative 
potential? 
 
Large heterogeneity; 
Heterotopic 
differentiation 
Heart 
 
Resident cardiac 
progenitor cells 
 
Robust cardiovascular 
differentiation 
potential; Electrically 
integrated 
Stem cell pool appears to 
undergo senescence 
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The autologous cell therapy approach has been  applied to bone marrow stem cells, SMs, and 
adipose tissue stromal cells (Murry et al. 1996; Makino et al. 1999, Taylor et al. 1998, Zuk et 
al. 2001 and Condorelli et al. 2001). Recently, adult heart progenitor cells that have the 
potential to differentiate into mature cardiomyocytes have been reported (Beltrami et al. 
2003, Messina et al. 2004). 
In contrast, the methods to quickly and efficiently amplify mouse embryonic stem cells into 
various types of cells in vitro have been developed. A number of research groups have 
demonstrated the ability for mouse embryonic stem cells to differentiate into cardiomyocytes 
(Fijnvandraat et al. 2003, Fijnvandraat et al. 2003, Klug et al. 1996). In 1998, the first human 
embryonic stem cells were established and thereafter, hundreds of characterised human 
embryonic stem cell lines have been derived worldwide. Human embryonic stem cells can 
differentiate into cells representing all three embryonic germ layers (Itskovitz-Eldor et al. 
2000), including neurons (Reubinoff et al. 2001), cardiomyocytes (Kehat et al. 2001), 
hematopoietic cells (Kaufman et al. 2001), and endothelial cells (Levenberg et al. 2002), 
making them an extremely interesting cell source. Recently, studies have shown that it is 
possible to generate pluripotent stem cells from mouse and human embryonic or adult 
fibroblast cultures by introducing Oct3/4, Sox2, Klf4, and c-myc (Takahashi and Yamanaka 
2006; Okita et al. 2007). Although embryonic stem cells possess great potential they are 
nevertheless allogenic, presenting a risk of immune rejection.  
So far, SMs and bone marrow-derived stem cells are the most well characterised and studied 
cells for myocardial treatment in patients with ischaemic heart disease. The autologous origin 
of these cells solves problems related to immunoreactions. Also, their availability and high 
scalability potential allows prompt isolation and transplantation when needed (Durrani et al. 
2010). 
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2.3 Skeletal myoblasts 
The history of cell-based cardiac repair began with studies of SMs (Marelli et al. 1992; Chiu 
et al. 1995; Koh et al. 1993; Menasché et al. 2008). These are progenitor cells resident within 
skeletal muscle. These satellite cells can be isolated by skeletal muscle biopsies and are easily 
expanded in vitro (Marelli et al. 1992; Chiu et al. 1995; Koh et al. 1993), making them 
feasible in the setting of chronic myocardial dysfunction. They tolerate hypoxic conditions 
well and can differentiate into myotubes even in hypoxic environments (Augustin et al. 
2009). These cells were the first to be utilised in cardiac cell transplantation experiments and 
clinical trials and the first to be documented in case reports (Taylor et al. 1998; Menasché et 
al. 2008). 
Skeletal myoblasts have several advantages for heart cell therapy. Their availability from 
autologous sources bypasses the immunological and ethical considerations associated with 
some of the other cell types that become prohibitive when applied to humans. Easy ex vivo 
expansion and proliferation combined with superior resistance to ischaemia makes these cells 
attractive candidates for myocardial tissue cell therapy (Collins et al. 2005). 
Various research groups have studied SMs for the treatment of both ischaemic and non-
ischaemic cardiomyopathies in mouse, rabbit, sheep, dog, and pig models (Khan et al. 2007; 
Al Attar et al. 2003; Taylor et al. 1998; McCue et al. 2008; Ghostine et al. 2002; Brasselet et 
al. 2005; He et al. 2005; Haider et al. 2004; Ye et al. 2007; Chazaud et al. 2003; Hagege et al. 
2003). These experiments have shown that SMs prevent left ventricular remodelling, 
maintain global and regional parameters of myocardial contractility and also improve 
diastolic properties (McCue et al. 2008; Atkins et al. 1999). 
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Skeletal myoblasts are excellent carriers of therapeutic genes and have been genetically 
modified with both viral and non-viral vectors encoding different cytokines and growth factor 
genes in order to improve their functional characteristics in terms of survival, engraftment 
and differentiation (Elmadbouh et al. 2007; Murtuza 2004; Suzuki et al. 2001; Aharinejad et 
al. 2008). Non-viral gene delivery systems have also been successfully used in the 
modification of SMs (Elmadbouh et al. 2007; Ye et al. 2007). In addition, HS pre-treatment 
has been demonstrated to improve hypoxia tolerance in vitro (Augustin et al. 2010) and is 
suggested to be useful in improving graft cell survival in SM cell transplantation (Suzuki et 
al. 2000). Even though it is less efficient, the use of non-viral vector delivery and HS 
treatment overcomes the unwanted effects of viral vectors. A new and interesting 
development in this regard is the use of nanoparticle-based delivery of transgenes into human 
SMs (Ye et al. 2007).  
The limited survival of transplanted cells after injection is a critical issue. It has been shown 
that only ∼7.4% of injected cells survived past 72 h (Suzuki et al. 2004). It is obvious that the 
small number of surviving cells cannot contribute a substantial contractile force to the 
myocardium. SMs are one of the few cell types that do not normally express gap junction 
proteins. Structural and physiological studies have shown that skeletal muscle cells do not 
form electromechanical junctions with cardiomyocytes and this has caused serious 
arrhythmia cases in clinical studies (Reinecke et al. 2000; Scorsin et al. 2000; Menasché et al. 
2001; Rubart et al. 2004). Attempts are ongoing to enhance this therapeutic strategy by 
modifying SMs by genetic approaches and by developing new ways for cell delivery to 
ischaemic heart muscle (Hare & Chaparro 2008). 
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2.4 Mesenchymal stem cells 
The mammalian bone marrow consists of different elements (a heterogenous population of 
macrophages, fibroblasts, adipocytes, osteoprogenitors endothelial cells, and reticular cells) 
supporting haematopoiesis and bone homeostasis (Muller-Sieburg and Deryugina 1995; 
Zhang et al. 2003). Among these, there are cells possessing multi-lineage differentiation, non-
hematopoietic stem cells, that are indicated as marrow stromal stem cells or MSCs (Deans & 
Moseley 2000; Bianco et al. 2001).  
MSCs are self-renewing clonal precursors of non-haematopoietic stromal tissues. They can 
be isolated from bone marrow or adipose tissue and expanded in culture based on their ability 
to adhere to culture dishes and proliferation in vitro (Mangi et al. 2003; Dawn et al. 2009). 
MSCs have the capacity to differentiate into skeletal muscle (Ferrari et al. 1998), osteoblasts, 
chondrocytes (Pereira et al. 1995), neurons (Chen et al. 2001), and cardiac muscle (Makino et 
al. 1999; Toma et al. 2002). MSCs are a rich source of growth factors that contribute to 
cardiac repair by paracrine signalling and therefore have a significant role in facilitating 
cardiac repair after MI (Tang et al. 2004).  
In experimental settings, MSC-treated hearts showed an increase in tissue perfusion, a 
reduction in apoptosis, infarct size reduction, and dramatic improvements in global and 
regional cardiac function (Hare & Chaparro 2008). Experiments on human, baboon and 
murine MSCs showed that MSCs are immunosuppressive (Le Blanc et al. 2003; Djouad et al. 
2003). Their ability to target areas of injured tissue (Ramos & Hare 2007) makes them an 
appealing cell source candidate for an off-the–shelf, easy to administer therapy. MSCs have 
been tested in a phase I trial for patients with acute MI and are currently in phase I/II and 
phase II trials for heart failure and acute MI. 
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MSCs have been shown to secrete paracrine mediators (such as IGF, HGF, VEGF, and IL-6) 
with cardioprotective properties (Shabbir et al. 2009). They also provide a less invasive 
allogeneic cardiac regeneration therapy due to their suggested immune-privileged properties, 
and may therefore be better candidates for cardiac repair than other cells (Schuleri et al. 
2008). It is an attractive idea that allogeneic MSCs, prepared and stored in advance, would be 
equal in efficacy to autologously-transplanted cells. Despite promising results from early 
non-randomised clinical trials, larger clinical trials have been disappointing in regards of 
endpoints (Ankrum & Karp 2010). Literature shows evidence of allo-MCSs being immune-
privileged at some anatomical sites, or that the anti-donor immune tolerance might be 
controlled. However, the interaction between the host immunoreactions and the allo-MSCs is 
an overly complicated issue and needs further investigation. More critical analysis of the 
interaction between allogeneic cell therapies and the recipient immune system are needed for 
the development of this therapy approach (Griffin et al. 2010). 
However, as in the case of myoblasts, the low cellular survival rate after transplantation is 
problematic and those cells which survive after transplantation are not able to form mature 
cardiomyocytes that can integrate with their native neighbours. Attempts are ongoing to 
enhance this therapeutic strategy (Toma et al. 2002; Gross et al. 1999; Dai et al. 2005).  
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2.5 Mechanisms of stem cell action in the diseased heart 
Several preclinical and clinical studies have demonstrated that stem cell therapy is effective 
in treating ischaemic heart disease after MI. Since the biology of cardiac homeostasis is quite 
complex, the mechanisms behind these effects are diverse. Despite extensive efforts, the 
mechanisms by which stem cells promote cardiac repair remain controversial. It is likely that 
regeneration of the myocardium occurs via several pathways. Initially, it was suggested that 
transplanted cells are able to differentiate into cardiac cells, blood vessels, or other cells 
damaged by MI (Jackson et al. 2001; Condorelli et al. 2001; Orlic et al. 2001). However, this 
theory has been recently replaced by the idea that transplanted stem cells release growth 
factors and other molecules, promoting blood vessel formation (angiogenesis) or stimulating 
cardiac stem cells to repair damage (Kocher et al. 2001; Schuster et al. 2004; Gnecchi et al. 
2005). The fusion of transplanted cells with host cardiomyocytes has also been proposed 
(Nygren et al. 2004).  
The influence of cytokines restores coronary blood vessels and muscle cells after 
experimental infarction by angiogenesis (Anversa et al. 2006; Nadal-Ginard et al. 2003). 
Bone marrow stem cells express several cytokines such as vascular endothelial growth 
factors, insulin-like growth factors, and platelet-derived growth factors. These cytokines can 
increase the stimulation of residual normal myocytes for regeneration and proliferation, and 
intrinsic myocardial stem cells (endogenous stem cells) for cell regeneration and fusion 
(Bittner et al. 1999; Alvares-Dolado et al. 2003; Beohar et al. 2010; Leri et al. 2008).  
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Figure1. Proposed mechanisms of adult stem cell action in cardiac repair (Gnecchi et al. 
2008). 
 
2.6 Cell delivery routes 
The appropriate route for cell administration to the damaged organ is a vital qualification for 
the success of cell therapy. Regardless of the cell type used, clinical benefits are obtained 
only if a sufficient amount of cells are delivered to the area of interest and if the cells are 
retained at the delivery site. A number of techniques have been applied for delivering 
therapeutic progenitor cells or genes to the heart. The cell delivery can be performed through 
coronary arteries and veins, or peripheral veins. Also, direct intramyocardial injection can be 
performed, using a surgical, transendocardial, or transvenous approach (Perin & Silva 2010). 
Intracoronary infusion and intramyocardial cell delivery methods have been used in human 
trials (Britten et al. 2003; Assmus et al. 2002; Wollert et al. 2004; Chen et al. 2004; Henry et 
al. 2003; Herreros et al. 2003; Rosengart et al. 1999; Losordo et al. 1998; Vale et al. 2000; 
Smits et al. 2003). In animal models, cell delivery techniques used include infusion into the 
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coronary venous system (Hou et al. 2003; Boekstegers et al. 2000; Thompson et al. 2003) and 
the pericardial space (Hou and March 2003; Waxman et al. 2000). 
The easiest cell delivery route is intravenous. The main weakness of this method, however, is 
that when given intravenously, only a very small fraction of infused cells can reach the infarct 
region (Barbash et al. 2003; Abdel-Latif et al. 2007) and approximately 3% of normal cardiac 
output will flow per minute through the left ventricle (Strauer 1979). Therefore, many 
circulation passages are needed to enable infused cells to contact the area of interest, namely 
in the infarcted zone. Cell-homing to other organs reduces significantly the number of cells 
populating the infarcted area (Hofmann et al. 2005; Sussman 2001). 
In the intracoronary delivery method, the transplantable cells are injected into a target 
coronary artery through a balloon catheter by using a stop-flow technique. Coronary blood 
flow is stopped for several minutes while the cells are being infused in order to prevent a 
rapid outflow of the transplanted cells (Bui et al. 2010). The cells can be delivered at the site 
of the revascularised occlusion that caused the myocardial injury. This makes the 
intracoronary approach advantageous. Also, strong homing signals from damaged tissue may 
enhance cell retention and larger areas of dysfunctional myocardium may benefit from 
intracoronary delivery (Hou et al. 2005). Even though it is not technically difficult, this 
approach also has disadvantages. Cells have to travel through the vascular endothelium to 
injured sites, which can reduce the overall efficiency of the therapy.  
An alternative delivery method for cardiac cell transplantation is the endocardial catheter 
injection (Hofmann et al. 2005). This is performed via an injection catheter which is placed 
across the aortic valve into the target area (Perin et al. 2003; Losordo et al. 2007). The 
endocardial method offers intramyocardial cell delivery similar to the surgical approach, but 
is less invasive. In a clinical setting, the endocardial route has proven safety and feasibility in 
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chronic ischaemic heart disease. However, cell loss into the ventricle, incorrect injections 
sites, ventricular arrhythmias, and cardiac tamponade can occur (Perin et al. 2003).  
2.7 Cell sheet technology 
The choice of a cell delivery method has a crucial role in the efficacy of the therapy. Current 
cell transplantation methods by injection disturb not only the micro-intercellular 
communication but also the extracellular matrix of the transplanted cells. These are vital 
elements in cell adhesion, migration, proliferation, differentiation, and death (Kondoh et al 
2005). Therefore, the use of a cell delivery method that maintains cell-cell interactions is 
crucial for successful transplantation. Enzymatic digestion of cells by trypsin prior to cell 
transplantation can be disadvantageous for cell therapy. Trypsin treatment cleaves the cell 
surface receptors, disrupts the extracellular matrix and cell-cell contacts, compromises cell 
survival and growth, and has been suggested to be disadvantageous for cell therapy (Okano et 
al. 1993).  
Tissue engineering has been developed as a basic technology for regenerative medicine. The 
components used in tissue engineering methods have generally included isolated cells or cell 
substitutes, appropriate signalling molecules such as cytokines or growth factors, and 
extracellular matrix (ECM) proteins (Langer & Vacanti, 1993). When methods based on 
biodegradable polymers are used, the spaces occupied by the biodegradable polymers often 
become filled with large amounts of deposited ECM, resulting in reduced cell-to-cell 
connections in the resultant tissues. In addition, scaffold biodegradation can cause 
inflammatory responses and pathological fibrotic states (Masuda et al. 2008). 
A tissue-engineering methodology called cell sheet engineering makes it possible to avoid the 
shortcomings associated with biodegradable polymers. This technology is based on 
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temperature-responsive, polymer-grafted cell-culture dishes, which release the confluent cells 
from the dish surface at temperatures below 20°C (Masuda et al. 2008; Memon et al. 2005; 
Hirose et al. 2000).Several groups have adopted this technology and cell sheet engineering 
has been applied to skin (Yamato et al. 2001), corneal epithelia (Nishida et al. 2004a; Nishida 
et al 2004b), periodontal ligament cells (Akizuki et al. 2005), bladder epithelia (Shiroyanagi 
et al. 2003; Shiroyanagi et al. 2004), kidney glomeruli (Kushida et al. 2005; Kushida et al. 
2001), myocardial cells (Shimizu et al. 2006; Shimizu et al. 2006), hepatocytes (Harimoto et 
al. 2002), and MSCs (Miyahara et al. 2006). 
 
 
Figure2. Cell sheet detachment from temperature-responsive culture surfaces. When 
enzymatic digestion is used, cell-to-cell connections and the ECM are disrupted and cells are 
released separately. With the temperature-responsive culture surfaces, cell-to-cell connections 
and deposited ECM are preserved and the cells are released as a contiguous cell sheet. Cell-
to-cell connections are completely preserved and the cells are detached as a contiguous cell 
sheet. The ECM retained underneath the cell sheets works as an adhesive agent (Modified 
from Masuda et al. 2008).  
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2.8 Preconditioning of cells 
The majority of injected cells are lost quickly following transplantation, with only a few 
donor cells being able to survive (Pagani et al. 2003; Toma et al. 2002). The reasons behind 
this include host inflammatory response, and mechanical injury. Also, the source and quality 
of transplanted cells have an impact on post-transplantation survival. However, one of the 
main causes of cell loss is apoptosis (Hodgetts et al. 2000; Kharbanda et al. 2002). Factors 
activating apoptosis cascades include a lack of nutritional support, cells detaching from the 
extracellular matrix, and the activation of death receptors (Yamaoka et al. 2000). The 
mitochondrial membrane potential is reduced after the activation of apoptosis and pro-
apoptotic factors are released, including the activation of cytochrome C (Cyt C), 
endonuclease G, apoptosis-inducing factor (AIF) and caspase-3 (Logue et al. 2005).  
Preconditioning of cells prior to transplantation can significantly improve the resistance of 
cells to oxidative stress and inflammation following implantation (Kubo et al. 2008). It has 
been shown to increase the differentiation potential and paracrine activity of cells. Several 
studies have demonstrated that HS pre-treatment and anoxic and hypoxic preconditioning can 
enhance cell survival and facilitate their involvement in cardiac repair following MI (Rosová 
et al. 2008; Tang et al. 2009). Cell protection can also be achieved using anti-apoptotic 
preconditioning strategies like interleukin 1 (IL-1) or Bcl-2 gene modification. The use of 
receptor antagonists, the removal of the host complement C3, or the inhibition of humoral 
immunity using anti-CD154 antibodies before and after transplantation have also been used 
(Camirand et al. 2002; Hodgetts & Grounds 2001). Also, insulin like growth factor 1 (IGF-1) 
(Kofidis et al. 2004), vascular endothelial growth factor (VEGF), β-fibroblast growth factor 
(FGF), or HS treatment can be used to improve the survival of the transplanted cells 
following infarction (Hodgkinson et al. 2010; Haider et al. 2008; Kanemitsu et al. 2006). 
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2.9 Heat shock 
The HS response is a response to a mild stress, which allows cells to adaptat to gradual 
changes in their environment and to survive in otherwise lethal conditions. The HS response 
is characterised by the increased expression and accumulation of heat shock proteins (HSPs). 
Since many different stress conditions can increase the expression of heat shock proteins, 
these proteins are also referred to as stress proteins (Hegde et al. 1995; Li 1983). The very 
first data about HS response was published in 1962 when Ritossa et al. discovered a novel 
heat-inducible ‘puffing’ pattern in fruit fly salivary gland chromosomes (Jamrich et al. 1977; 
Ritossa 1962). 
The following intensive research on stress response developed into two major directions: 1) 
elucidation of molecular mechanisms underlying the heat shock response; and 2) 
characterisation of the structure and function of heat shock proteins (HSPs) (Leppä & 
Sistonen 1997; Morimoto & Santoro 1998). Studies on a genome-wide level have shown that 
roughly 50-200 genes are significantly induced in different model organisms during heat 
stress (Eisen et al. 1998; Gasch et al. 2000; Matsuura et al. 2010; Larkindale and Vierling 
2008; Richmond et al. 1999; Rohlin et al. 2005; Tabuchi et al. 2008).  
Functionally, stress-inducible proteins can be divided into seven classes (Richter et al. 2010). 
The main class, the initially discovered HSPs, is referred to as molecular chaperones (Ellis et 
al. 1989). The second and third class of HSPs are DNA/RNA repair and modifying enzymes, 
which are necessary to repair DNA damage and processing failures that occur during stress 
(Jantschitsch and Trautinger, 2003), such as the heat-induced methylation of ribosomal RNAs 
(Bugl et al. 2000). The fourth HSP class is composed of metabolic enzymes (Malmendal et 
al. 2006; Voit and Radivoyevitch, 2000). The fifth class is regulatory proteins and the sixth 
class comprises proteins involved in sustaining cellular structures. The seventh class of up-
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regulated proteins contains transport, detoxifying, and membrane-modulating proteins (Al 
Refaii and Alix 2009; Welker et al. 2010). HSPs are also classified according to their 
molecular weight: large HSPs of 100-110kDa, the Hsp90 family, the Hsp70 family, the 
Hsp60 family, the Hsp40 family, and small HSPs of 18-30kDa (Lindquist and Craig 1988; 
Jäättelä et al. 1999; Richter et al. 2010). 
Hsp70 proteins share about 60% sequence identity with eukaryotic Hsp70 proteins, which are 
found in the cytosol and in organelles such as the ER, mitochondria and chloroplasts (Mayer 
and Bukau 2005; Richter et al. 2010). Under normal conditions, Hsp70s function as ATP-
dependent molecular chaperones, with their main role involving assisting in several folding 
processes (folding of newly-synthesised proteins, refolding of misfolded and aggregated 
proteins, membrane translocation of organellar and secretory proteins, and control of the 
activity of regulatory proteins) (Hartl & Hayer-Hartl 2002; Young et al. 2003; Ryan & 
Pfanner 2001; Pratt & Toft 2003). Under different stress conditions, the synthesis of Hsp70 
enhances the ability of stressed cells to cope with increased concentrations of unfolded and/or 
denatured proteins (Shi and Thomas 1992; Chiang et al. 1989; Nollen et al. 1999). Moreover, 
Hsp70 can effectively inhibit cellular death processes, apoptosis or necrosis, and thereby 
increase the survival of cells exposed to a wide range of lethal stimuli (Jäättelä et al. 1992; 
Arya et al. 2007; Zhao et al. 2007; Benjamin et al. 1998; Jiang et al. 2011). Heat shock (HS) 
has served as a preconditioning method prior to myoblast transplantation (Kojima et al. 2007; 
Bouchentouf et al. 2004). It has been suggested that by using HS as a preconditioning 
method, there is no need to modify the cells genetically before transplantation.  
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2.10 Genetic engineering 
Gene therapy is used for the correction of genetic defects or the expression of therapeutically-
efficient gene products. The latter is a potential approach for treating cardiovascular diseases, 
by causing expression of the therapeutic factors locally or systemically (Morgan & Anderson 
1993; Nabel 1994; Nabel 1999). Gene therapy advantages are the long-term expression of the 
therapeutic agent and also the possibility to target the treatment to the desired tissue (Ylä-
Herttuala and Alitalo 2003). In order for gene therapy to be effective the gene-transfer system 
needs to be reliable and successful. The therapeutic approach has to be designed to best suit 
the treated condition. The choice of viral vector, delivery method and therapeutic gene 
defines the location and duration of the production of therapeutic proteins (Kay et al. 2001). 
For optimal gene delivery to target cells, characteristics of the cell must be considered, such 
as proliferative capacity and location within the target tissue (Nabel 1995). The properties of 
therapeutic proteins (solubility, interactions with endogenous molecules, immunogenicity) 
also further tailor the therapeutic response. 
2.11 Angiogenic gene therapy 
Vascular endothelial growth factor (VEGF) is a main regulator of physiological angiogenesis 
during embryogenesis, skeletal growth and reproductive functions. This, perhaps the most 
highly investigated angiogenesis-inducing growth factor, has a well-documented in vitro 
ability to promote the growth of vascular endothelial cells (ECs) derived from arteries, veins 
and lymphatics (Ferrara et al. 1997). VEGF is shown to be an inducer of potent angiogenic 
responses in a variety of in vivo models (Leung et al. 1998). VEGF has been shown to have 
mitogenic effects also on certain non-EC types (Hagberg et al. 2010). It also induces 
lymphangiogenesis in mice (Nagy et al. 2002) and has been shown stimulate surfactant 
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production by alveolar type II cells (Compernolle et al. 2002). The mammalian genome 
encodes five isoforms of the VEGF family (VEGF-A, VEGF-B, VEGF-C, VEGF-D and 
placental growth factor) that bind to endothelial cells (Ferrara 1999; Zhao et al. 2010). 
VEGF-A is one of the strongest known inducers of vascular permeability, which occurs 
within minutes of exposure to VEGF-A. Since VEGF-A has a major role in vascular biology 
and because of its high angiogenic potency this isoform has been the prime candidate for 
therapeutic applications in vivo (Ylä-Herttuala et al. 2007)  
2.12 Anti-apoptotic gene therapy 
Bcl-2 family proteins have been studied intensively for the past decade. They have an 
essential role in the regulation of apoptosis, tumourigenesis and cellular responses to anti-
cancer therapy. Bcl-2 family proteins have either pro- or anti-apoptotic activities (Youle and 
Strasser 2008; Gustafsson & Gottlieb 2007). Bcl-2 is an anti-apoptotic member of the Bcl-2 
family of apoptosis-related proteins. It is localised intracellularly to mitochondrial, nuclear, 
and endoplasmic reticulum membranes (Adams & Cory 1998), and has been shown to protect 
cells from death stimuli, such as nutrient deprivation, by stabilising the mitochondrial 
membrane potential, reducing caspase activation, or inhibiting cytochrome c release (Yang et 
al. 1997; Crow et al. 2002). 
Over-expression of Bcl-2 has been shown to enhance cell survival and to inhibit cell death 
induced by apoptosis-inducers, such as staurosporine, or by nutrient deprivation (Kitabayashi 
et al 2010). Bcl-2 has been suggested to be a valuable regulator of early donor 
cardiomyoblast or mesenchymal stem cell death in models of acute MI. Bcl-2 gene therapy 
has been used in cardiac cell therapy to prevent apoptosis upon cell injection into the 
myocardium (Kutschka et al. 2006; Li et al. 2007). Also, it has been shown that Bcl gene 
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therapy of myoblasts enhances their production of paracrine mediators, prolongs graft 
survival, and improves cardiac function (Kitabayashi et al. 2010).  
2.13 Clinical trials of cardiac cell therapy 
2.13.1 Myoblasts 
 
Cardiac cell therapy has been in clinical testing for 10 years now. Both autologous SMs and 
different bone marrow-derived cells (mononuclear cells, haematopoietic progenitors, MSCs) 
have been investigated in different settings (Menasché 2011). Autologous skeletal myoblasts 
need several weeks of ex vivo cultivation prior to transplantation and, therefore, these trials 
have mainly been performed in patients with chronic heart failure, rather than in those with 
acute myocardial infarction (Jain et al. 2001). These trials have demonstrated that hundreds 
of millions of skeletal myoblasts can be grown from muscle biopsies and thereafter 
successfully injected into the heart without early procedural complications (Menasché et al. 
2008; Dib et al. 2005; Gavira et al. 2006). 
After ∼10 years of preclinical testing in more than 40 studies, skeletal myoblasts were the 
first to be tested in clinical trials (Menasché et al. 2001). Menasché et al. performed the very 
first myoblast transplantations (Menasché et al. 2001; Menasché et al. 2003; Menasché et al. 
2008), where 800 million cells were transplanted into a patient undergoing coronary artery 
bypass grafting (CABG) surgery. Symptoms were relieved but unfortunately the patient died 
17 months after the operation due to stroke caused by acute proximal subclavian artery 
occlusion. Autopsy showed the presence of multinucleated myotubes embedded within the 
fibrosis measuring up to 4mm in length without any inflammation, fibrosis or 
neovascularisation. These cells were aligned in the same direction as the adjacent 
cardiomocytes (Hagege et al 2003). In another study conducted by Menasché et al. (2003), 
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ten patients received average of 871 x 106 autologous myoblasts in the infarct area. The 
patients had severe left ventricular dysfunction with LVEF less than 30%. After cell 
transplantation, four patients developed sustained ventricular tachycardia and were implanted 
with an internal defibrillator. Echocardiography showed an improvement in systolic function 
in 63% of the cell-implanted scar segments (Menasché et al. 2003).  
Shortly after these, Siminiak et al. (2004, 2005) published results from phase I/II clinical 
trials. One was associated with GABG surgery and another used a percutaneous catheter 
delivery system (Siminiak et al. 2003; Siminiak et al. 2004; Siminiak et al. 2005). In the 
CABG trial, the left ventricular EF improved significantly (by 5% on average) after myoblast 
administration, documenting both the feasibility as well as the benefit of the approach 
(Siminiak et al. 2004). In the second trial (POZNAN trial), cells were delivered via the 
coronary venous vessels associated with the arteries supplying the infarcted heart segments 
(Siminiak et al. 2005). This transcoronary venous access (TransAccess catheter system) study 
included 10 patients with previous MI and suggested improved heart haemodynamic 
parameters (EF increased 3%–8%). However, arrhythmic episodes were frequently noted, 
necessitating the application of implantable cardioverter defibrillators. 
Herreros et al. (2003) used direct transepicardial myoblast injections simultaneously with 
CABG in a group of 12 patients. Echocardiography showed improvements in regional 
contractility in cardiac segments treated with skeletal myoblasts. After 3 months a significant 
increase in cardiac viability in the infarct area was shown by PET studies (Herreros et al. 
2003). Dib et al. reported a study using direct transepicardial injections at a simultaneous 
CABG operation. 24 patients underwent CABG and intramyocardial injections of 10-300 x 
106 cells in a dose-escalating manner. Another 6 patients waiting for heart transplantation 
received a left ventricular assist device (LVAD) and intramyocardial injection of 300 x 106 
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myoblasts (Dib et al. 2005). No deaths or arrhythmias occurred during surgery or injection of 
the cells. Results showed an improvement in EF, as well as induced metabolic activity at 
injection sites, with no adverse effects detectable. Three deaths in the LVAD and 1 in the 
CABG group occurred during the four year follow-up period. None of them were related to 
the cell transplantation procedure. Also, in a study by Gavira et al., 12 patients with previous 
MI and ischaemic coronary artery disease received intramyocardial injections of myoblasts 
during CABG. After one year follow-up, LVEF, regional contractility, and perfusion 
improved significantly (Gavira et al. 2006) 
The first phase II trial, the Myoblast Autologous Grafting in Ischaemic Cardiomyopathy 
(MAGIC) trial, involved 21 European centres and evaluated myoblast transplantation in 
patients with severe left ventricular dysfunction, a non-viable post-infarction scar, and an 
indication for CABG (Menasché et al. 2008). This trial was originally designed to include 
300 patients but was stopped early, after 120 patients, when the data safety and monitoring 
board determined that the study was unlikely to show a benefit of treatment. Ultimately, only 
97 patients were effectively treated. Despite the high expectations, this trial failed to show 
any improvement in global or regional left ventricular function. Although no significant 
differences in arrhythmias were detected in the myoblast group compared to the placebo 
group, there was a tendency for early post-operative arrhythmias. 
2.13.2 Bone marrow cells 
Unlike in SM cell therapy, hundreds of millions of autologous bone marrow-derived cells can 
be obtained without the need for long ex vivo expansion time. This has enabled most clinical 
studies to be aimed mainly towards the treatment of patients with recent acute myocardial 
infarction. Several studies have suggested that intracoronary injection of mixed populations 
of bone marrow stem cells or of MSCs could represent a simple and successful approach to 
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the treatment of heart diseases (Strauer et al. 2003; Chen et al. 2004; Wollert et al. 2004). 
Over the last three years, there have been steady advances in stem cell research and therapies 
to address some of the most daunting medical challenges, including heart disease and stroke 
(Copeland et al. 2009).  
2.13.2.1 Bone marrow-derived mononuclear cells  
Bone marrow-derived mononuclear cells (MNC) infused through the recently reopened 
infarct-related coronary artery have been the most widely investigated in patients suffering 
acute myocardial infarction (Menasché et al. 2010). A recent meta-analysis compiled data of 
13 randomised trials (811 patients) with a 3- to 6-month follow-up. This analysis concluded 
that stem cell therapy improved LVEF by 2.99%, reduced LV end systolic volume by 4.74ml, 
and reduced myocardial lesion area by 3.51% compared with controls. However, bone 
marrow cell therapy failed to alter post-infarction remodelling, which is a major predictor of 
late adverse outcome (Udelson et al. 2002). 
The Reinfusion of Enriched Progenitor Cells and Infarct Remodelling in Acute Myocardial 
Infarction (REPAIR-AMI) trial is the largest 204-patient trial so far reporting a reduction in 
the 2-year incidence of major adverse cardiovascular events (Schächinge et al. 2006; Assmus 
et al. 2012). The HEBE trial including 200 patients showed no improvement in LVEF at 4 
months. Study groups were bone marrow-derived cells, peripheral blood-derived cells and 
standard therapy. A post-hoc analysis demonstrated that treatment prevented further 
remodelling in patients with initially dilated ventricles (van der Laan et al. 2008). The 
REGENT trial randomised 200 patients into a non-blind control group, an unfractionated 
bone marrow-derived mononuclear cell MNC group or select CD34+ CXCR4+ cell group. 
Unfortunately this trial also failed to show a difference in LVEF or volumes after 6 months 
(Tendera et al. 2009). 
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A trial reporting a positive outcome is the FINCEL trial, which randomised 80 patients into a 
group receiving intracoronary infusions of bone marrow mononuclear cells or a placebo 
group. LVEF was measured by left ventricular angiography and 2-D echocardiography. After 
6 months, BMC-treated patients had a greater absolute increase of global LVEF than placebo-
treated patients (Huikuri et al. 2008). 
Perin et al. (2003) have demonstrated the efficacy of bone marrow mononuclear cells in 
treatment of end-stage ischaemic heart disease. This study showed that bone marrow 
mononuclear cells in patients with end-stage ischaemic heart disease may promote 
neovascularisation and may prevent impairment of heart functionality, which in turn can lead 
to myocardial infarction. The 4-month follow-up revealed an improvement in ejection 
fraction and a reduction in end-systolic volume in the treated patients (Perin et al. 2003). 
 
2.13.2.2 Mesenchymal stem cells 
At present there is a paucity of human clinical MSC trials for the treatment of cardiovascular 
disease. Most clinical trials to date have focused on unfractionated BM cells that contain a 
very low percentage of MSCs ( 1 in 100,000). However, there are several MSC clinical trials 
currently starting or underway and, as results are revealed over the next few years, the 
viability of therapeutic MSCs used to treat heart disease will become clearer (Trivedi et al. 
2010; clinical trials.cov 16/07/2012).  
The Provacel™ study evaluated the effects of intravenously injecting allogenic MSCs in 
patients with acute myocardial infarction (34 and 19 patients in the treated and control 
groups, respectively). After 6 months, the improvement in LV function compared with 
baseline values was greater in treated patients than in controls (Hare et al. 2008). In this study 
the intravenous approach was used which gave a low cell-homing rate due to cell trapping in 
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the lungs. A subsequent study by Lee et al. has shown that this stem cell pulmonary 
sequestration might be associated with the release of an anti-inflammatory mediator (TSG-6) 
which might have contributed to the reported benefits of MSC (Lee et al. 2010). This study 
has importance because of its safety data documents which are able to pave the way for the 
use of readily available off-the-shelf MSC-based cell products which have guaranteed batch 
consistency and functionality (Menasché 2011). 
2.13.3 Challenges of cardiac cell therapy 
Despite very promising clinical outcomes, the results for both acute myocardial infarction 
and chronic heart disease have been mixed and are therefore difficult to compare. Reasons for 
the variation of the results can be explained by the non-standardisation of protocols. These 
include cell preparation, timings of injections, baseline patient characteristics and methods of 
evaluation of cardiac function (Rosenzweig 2006). Also, differences in study design make 
comparisons difficult. Although most studies have been at least partially blinded during 
follow up, only a few of them have been carried out with blinded placebo treatments in their 
recruited controls (Janssens et al. 2006; Schachinger et al. 2006). More experimental and 
clinical studies are needed to address some of the key findings from the previous studies. 
These include cell preparation, dosing and timing of delivery, and also the delivery method 
(Menasché 2011; Trounson et al. 2011). 
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3. AIMS OF THE STUDY 
The aim of the present study was to develop preconditioning methods for skeletal myoblasts 
and bone marrow derived mesenchymal stem cells prior to transplantation in such way that 
they better tolerate and cope with hypoxic target tissue conditions promoting 
neovascularisation of infarcted myocardium. 
The specific aims of the individual studies were:  
 
I. To study the effect of heat shock pre-treatment on myoblast differentiation 
under hypoxic conditions. 
II. To test the hypothesis whether heat shock pre-treatment affects the angiogenic 
properties of myoblast sheets in vitro and in vivo. 
III. To investigate the effect of proangiogenic vascular endothelial growth factor 
(VEGF)-modified mesenchymal stem cell (MSC) sheet transplantation therapy 
in an experimental acute MI model. 
IV. To study metabolic activity differences between VEGF and Bcl-2 over-
expressing MSCs under stress conditions. 
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4. MATERIALS AND METHODS 
4.1 Animal care and ethical statement 
All experimental procedures were conducted according to the US National Institute of Health 
Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 
1996), and were approved by the ethics committee of the Helsinki University Central 
Hospital, Helsinki, Finland (STH420A, ESL-2008-05359/Ym-23). 
4.2 Treatment and anaesthesia of the animals (II, III) 
Animals used were Wistar Han rats (250-400g Harlan Laboratories, Rossdorf, Germany). For 
surgical procedures, animals were anaesthetised subcutaneously with medetomidine 
(0.05mg/kg s.c., Domitor®; Orion Pharma Inc.) and ketamine (5mg/kg i.p., Ketalar®; Parke-
Davis). Normal body temperature was maintained with a thermal plate throughout the 
operation. After the operation, anaesthesia was partially antagonised with atipamezole 
hydrochloride (1.0mg/kg s.c., Antisedan®; Orion Pharma Inc.). Buprenorphine 
hydrocholoride (0.05mg/kg s.c., Temgesic®; Reckitt and Colman Ltd.) was administered for 
postoperative analgesia.  
4.3 LAD ligation and sheet implantation (II, III) 
The animals were anaesthetised, intubated and ventilated during surgery. Body temperature 
was maintained with a thermal plate. MI was induced by ligation operation as follows: The 
heart was exteriorised through a left thoracotomy and pericardiotomy and LAD was ligated 
with a suture 3mm from its origin. Immediately after LAD ligation two cell sheets each 
consisting of 6x106 cells (myoblast, study II and MSCs, study III) were placed on the left 
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ventricular anterior wall. After the operation, the heart was returned to its normal position and 
covered with the pericardium. Control animals underwent the same procedures without sheet 
implantation, and sham-operated animals were operated on without LAD-ligation and sheet 
implantation. Animals were euthanised 4 weeks after the operation.  
4.4 Myoblasts (I, II) 
Myoblasts used in this study were from the C2C12 mouse myoblast cell line (CRL-1772, 
ATCC, Manassas, VA) and the L6 rat myoblast cell line (CRL-1458, ATCC, Manassas, VA) 
from the American Type Culture Collection. Cells were cultured in DMEM supplemented 
with 10% foetal calf serum (FCS) (Gibco, Paisley, Scotland), antibiotics (antibiotic-
antimycotic: penicillin 100μg/mL, streptomycin sulphate and 0.25μg/mL amphotericin B as 
fungizone, Gibco), under normal cell culture conditions (+37°C in a humidified atmosphere 
containing 5% CO2) and were used at passages 5-20.  
4.5 Mesenchymal Stem cells (III, IV) 
Mesenchymal stem cells used in this study were from the bone marrow of adult Fisher 344 
rats (SCR027, CHEMICON/Millipore). Cells were cultured in MSC expansion medium 
supplemented with antibiotics under normal cell culture conditions (+37°C in a humidified 
atmosphere containing 5% CO2) and were used at passages 5-20.  
4.6 Heat Shock and Hypoxia (I, II) 
Heat shock was induced by subjecting C2C12 myoblasts and L6 cell sheets to hyperthermia 
(+42°C for 45 min) in a water bath. Thereafter, cells were left to recover for 24 hours under 
standard culture conditions (study I) prior to the induction of differentiation and hypoxia. The 
recovery time of cell sheets was 4 to 5 hours prior to transplantation (study II). Hypoxia at an 
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oxygen concentration of 1% was induced by culturing cells/cell sheets in an air-tight modular 
incubator chamber/anaerobic workstation (In Vivo2, Hypoxia Workstation 400; Ruskinn Life 
Sciences Ltd, Bridgend, UK). 
4.7 Myoblast differentiation (I) 
Differentiation of myoblasts was initiated by changing the growth medium (DMEM with 
10% calf serum) to differentiation medium DM (DMEM supplemented with 2% horse 
serum). 20 000 cells/cm2 were plated on gelatin-coated six-well plates, and were maintained 
for 24 h to reach 90% confluence prior to the induction of differentiation. 
4.8 Caspase inhibition (I) 
Confluent C2C12 cultures were subjected to hyperthermia (+42°C for 45 min) in a water bath 
and transferred to normal culture conditions (+37°C in a humidified atmosphere containing 
5% CO2) for 24 h. After a recovery period, cells were transferred to DM (2% horse serum), 
caspase-3 inhibitor Z-DEVD-FMK (25μM) (Calbiochem, Darmstad, Germany) was added, 
and hypoxia (1% O2) was introduced as described above. 
4.9 Western blotting (I-III) 
Western blotting samples were prepared using SDS-PAGE sample loading buffer (Bio-Rad 
Laboratories, Redmond, WA, USA) supplemented with Complete Miniprotease inhibitor 
mixture tablets (Roche, Mannheim, Germany) and boiled for 5 min. Samples were separated 
by SDS-PAGE (gradient of polyacrylamide 5% to 15% with 4% stacking gel) and proteins 
were electrophoretically transferred to a nitrocellulose membrane (Schleicher and Schuell, 
Dassel, Germany). The membrane was then blocked with 2.5% low-fat dry milk in Tris-
buffered saline (20mM Tris- HCl, 150mM NaCl, and 0.1% Tween 20, pH 7.5), and was 
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incubated with primary antibodies, followed by incubation with an alkaline phosphatase-
conjugated secondary antibody (Promega). The protein bands were visualised according to 
manufacturer's recommendations. Densitometry of images was performed by the ImageJ 
program (Rasband, W.S., ImageJ, U. S. National Institute of Health, Bethesda, Maryland, 
USA, http://rsb.info.nih.gov/ij/, 1997–2008). 
4.10 Antibodies and reagents for Western blotting (I-III) 
The antibodies used in this study were: Anti-actin, Bcl-2, Bax, p-38 and anti-p21 (Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-Hsp70 (Stressgen, Victoria, BC, Canada), anti-Hsp90 
(Cell Signalling Technology Inc, Danvers, MA), Anti-troponin T (Sigma Chemical Co., St. 
Louis, MO), anti-myogenin, (F5D Developmental Studies Hybridoma Bank (DSHB), 
University of Iowa), MHC (myosin heavy chain MF20, DSHB), anti-PCNA (Neo Markers, 
Fremont, CA), anti-p27 kip1 (BD Biosciences, Bedford, MA), anti-caspase-3 specific for the 
active cleaved fragment and anti-Hsp90 (Cell Signalling Technology Inc, Danvers, MA), and 
p-p38 (anti-p38 MAP kinase, Sigma). Alkaline phosphatase (AP)-conjugated secondary 
antibodies anti-mouse IgG, and anti-rabbit IgG were from Promega (Madison, WI) and the 
AP-conjugated anti-mouse IgM was from Jackson ImmunoResearch Europe Ltd. (Soham, 
UK). 
4.11 Transfections (III, IV) 
A lentiviral vector carrying the human-VEGF-A-gene (AIV Institute University of Kuopio, 
Ylä-Herttuala group) was introduced to cells by 24h incubation in the presence of 8μg/ml 
polybrene (Sigma-Aldrich, St. Louis, MO). For Bcl-overexpression, MSCs were treated with 
retroviral pBabepuro-bcl2 (Dr. Juha Klefström, University of Helsinki) incubation for 48 
hours in the presence of 8μg/ml polybrene (Sigma-Aldrich, St. Louis, MO). Retrovirally-
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transfected cells were then selected with 2μg/ml puromycin (Sigma) for 48 h. The expression 
levels were determined by ELISA and western blotting. Non-transfected cells were used as 
controls. 
4.12 ELISA (II, III) 
An enzyme-linked immunosorbent assay (ELISA) was used to determine the amount of 
VEGF secreted by L6 myoblasts and lentivirally-transfected MSCs. The growth medium was 
collected and centrifuged. The concentration of VEGF was determined by R&D systems’ 
VEGF immunoassay according to the manufacturer’s protocol.  
4.13 Metabolic activity (IV) 
Cells were grown in 96-well plates and cultured under normal growth conditions. After 24 
hours of culturing the growth medium was changed to either serum free medium or 
staurosporine medium (10ng/ml; Sigma-Aldrich, St Louis, MO, USA). Cell 
viability/metabolic activity was assayed using the WST-1 Cell Proliferation Reagent after 24 
and 48 hours (Roche Diagnostics) according to the manufacturer’s instructions. Cell 
Proliferation Reagent WST-1 (Roche Diagnostics) was added to the wells and the plates were 
incubated for 2 h by shaking at 37°C before measuring the intensity of formazan product 
absorbance at 440nm (Varioskan, Thermo Electron, Vantaa, Finland). 
4.14 Cell sheet preparation (II, III) 
The cell sheets were prepared by plating 6 million cells (myoblasts, MSCs) on temperature-
responsive culture dishes (Cell Seed Up Cell, Tokyo, Japan) and leaving to grow under 
normal culture conditions for 24h. Prior transplantation cell sheets were harvested by a 
simple temperature change from 37°C to 21°C. 
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4.15 Echocardiography (II, III) 
The echocardiographic measurements were performed at 3, 10, and 28 days after surgery 
with a 7.5MHz transducer (MyLabR25, Esaote SpA, Genoa, Italy). The anterior wall 
thickness was measured during end-systole (AWTs) and end-diastole (AWTd), as was 
posterior wall thickness during end-systole (PWTs) and end-diastole (PWTd) phases. Left 
ventricular internal diameter at end-systole (LVDs) and end-diastole (LVDd) were measured 
similarly in the short-axis right parasternal projection just between the mitral valve and 
papillary muscles. LVDd and LVDs served to calculate fraction shortening (LVFS) and 
ejection fraction (LVEF): LVFS (%) = (LVDd-LVDs)/LVDd LVEF (%) = (LVDd3-
LVDs3)/LVDd3. 
4.16 Histology and immunostaining (II, III) 
At the end of the study follow-up, the animals underwent echocardiography and were 
sacrificed. The excised heart was cut into four equal transverse parts. The two middle parts 
were fixed in 4% neutral-buffered formalin for 48 hours, embedded in paraffin and cut into 
4μm-thick sections. Immunofluorescence staining was performed to identify vascular 
structures and cell proliferation. To demonstrate vascular density, endothelial cells were 
stained with an antibody against von Willebrand Factor (vWF, AB7356, Millipore, Billerica, 
MA). Cell proliferation was evaluated with an anti-Ki67 antibody (RM-9106-S1, Labvision 
Inc., Fremont, CA). The immunolabelled sections were examined under an Olympus IX81 
fluorescent microscope. The vWF- and Ki67-immunostained sections from each of the infarct 
and border areas were photographed with a microscope in two to three randomly selected 
microscopic fields and visually analysed. 
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4.17 Determination of infarct size (II, III) 
Fibrosis was evaluated from scanned images of picric acid-stained sections. The percentage 
of fibrosis was calculated as the picric acid-stained area divided by the whole section area as 
evaluated by use of Image J / Photoshop 7.0 (Adobe Inc, San Jose, CA). 
4.18 Microscopy methods (I-III) 
The morphology of the cultured cells was observed by reverse-phase contrast microscopy 
(Olympus Research inverted microscope CKX41), and pictures were taken with an Olympus 
DP12 digital camera (Melville, NY). The immunolabelled tissue sections were examined 
under an Olympus IX81 fluorescent microscope. 
4.19 Statistical analysis (I-IV) 
Data are presented as mean±standard error of the mean. Comparisons of parameters between 
groups were made with unpaired Student’s t test or ANOVA where applicable. The 
differences were considered significant when p<0.05. Statistical analyses were performed 
with Graph Pad Prism 4.0 (GraphPad Software Inc., San Diego, CA). 
- 43 - 
 
5. RESULTS 
5.1 Heat shock studies 
5.1.1 Heat shock and myoblast differentiation under hypoxic growth 
conditions (I, II) 
C2C12 SM cultures and L6 SM cell sheets were subjected to hyperthermia (+42°C for 45 
minutes) in a water bath. As a control for HS efficiency, the expression levels of Hsp70/72 
and Hsp90 were assessed. HS markedly induced the expression of Hsp70/72 and induced 
Hsp90 expression to a lesser extent in C2C12 cells. After their initial induction under both 
normoxic and hypoxic conditions, the induced levels of these HSPs declined. In L6 sheets, 
HSP70/72 expression of was strongly induced 24 hours after HS and remained stable under 
normal growth conditions. In hypoxia, HSP70/72 expression reduced significantly within 72 
hours (p<0.05 compared to controls). Sheet formation itself induced no HSP70/72 
expression. 
After recovery from HS, the C2C12 cells were cultured for up to 3 d in DM under normoxia 
or under 1% hypoxia. The expression of the myoblast differentiation-associated proteins 
troponin T, myosin and MHC were evaluated. The expression of troponin and myosin were 
lower in cells grown under hypoxia than in cells under standard culture conditions in control 
cells suggesting that low oxygen supply inhibits differentiation. HS pre-treatment enhanced 
the troponin expression in hypoxia, whereas HS did not have any effect on differentiation in 
cells cultured under normoxic conditions. HS had no effect on the expression of myogenin. 
Expression of MHC was induced by SM differentiation, but no differences were detectable 
between normal growth conditions or hypoxia cultured cells and HS did not have any effect 
on MHC expression levels. 
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5.1.2 Effects of heat shock preconditioning on apoptosis associated 
mitochondrial proteins, cell proliferation and caspase-3 cleavage (I) 
The expressions of mitochondrial apoptosis-associated proteins, Bcl-2 and Bax, were studied 
under normal and hypoxic growth conditions. HS had no effect on Bcl-2 and Bax expression 
under normal oxygen status. In hypoxia, both of these proteins were down-regulated after the 
first day of differentiation. This suggests a non-selective down-regulation of mitochondrial 
proteins and an increased susceptibility to apoptosis. HS preconditioning had no effect on the 
expression of Bcl-2 or Bax proteins under hypoxia. 
To evaluate the effect HS on SM proliferation, the expressions of proliferating cell nuclear 
antigen (PCNA) and levels of the cell cycle regulating cyclin-dependent kinase inhibitors 
p21CIP/WAF1 and p27Kip were assessed. PCNA expression decreased after day 1 under normal 
growth conditions and was associated with SM differentiation. Hypoxia delayed this PCNA 
decrease in heat-shocked cells. The expression of p21 remained constant in control cells 
under normal growth conditions, but expression in HS-cells was transiently increased. The 
expression of p27 remained stable under normal growth conditions despite the pre-treatment. 
A hypoxic environment decreased p21 expression immediately and p27 after day 1. 
The expression of the active, cleaved form of caspase-3 of SMs differentiated either under 
normoxia or 1% hypoxia was evaluated either with or without HS pre-treatment. Caspase-3 
expression increased temporarily one day after the initiation of differentiation, under both 
culture conditions. HS preconditioning sustained the increase of caspase-3 only in hypoxia 
but not under normal growth conditions, suggesting a hypoxia-selective delayed action of HS 
on caspase-3 activation. 
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5.1.3 Sheet apoptosis, resistance to oxidative stress and proliferation (II) 
To study SM sheet resistance to oxidative stress we evaluated the expression of caspase-3 of 
L6 SM sheets with or without HS pre-treatment under normal and hypoxic growth conditions. 
Under normal growth conditions, there was no significant difference in caspase-3 expression 
between non-shocked and heat shocked cell sheets during 72 hours. However, in hypoxia, the 
caspase-3 expression of heat shocked sheets was significantly lower (p<0.01) compared to 
no-shock sheets after 24 hours, suggesting an anti-apoptotic effect of heat shock pre-
treatment. 
5.1.4 Heat shock, caspase-3 inhibition and myoblast differentiation in 
hypoxia (I) 
Skeletal muscle differentiation has been reported to be dependent on caspase-3 activity 
(Fernando et al. 2002). To investigate how the inhibition of caspase-3 changes myogenesis 
under pathological hypoxia, we subjected cells to a caspase-3 inhibitor and evaluated 
differentiation under pathological (1% O2) hypoxia for 3 d. The control cells were treated 
with vehicle (DMSO). The expression of troponin T, Hsp-70, and caspase-3 were determined 
by western blot analysis. We found that differentiation-associated troponin T expression 
decreased by 65% (relative densitometry values 0.35 for Z-DEVD-FMK-treated and 1 for 
vehicle-treated cells) in the non-shocked cells. After HS preconditioning prior to the 
induction of differentiation under hypoxia the reduction in troponin T expression caused by 
the caspase-3 inhibitor was only 42% (relative densitometry values 1.7 and 1 for the HS-pre-
treated cells treated with Z-DEVD-FMK or vehicle, respectively, compared with non-
shocked cells). 
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5.1.5 VEGF-A secretion of L6 myoblast sheets in hypoxia (II) 
To study the potential paracrinic effect of HS-preconditioned SM sheets, we determined the 
secretion of VEGF under hypoxic conditions up to 72 hours. HS did not enhance L6 SM 
sheet VEGF secretion under hypoxic conditions. On the contrary, VEGF secretion was 
significantly lower (p<0.05) in HS-conditioned sheets than in non-conditioned (no-shock) 
sheets during follow up (no-shock: 24 h 10 740 ± 3 830pg/ml, 48h: 12 390 ± 1 242pg/ml 72h: 
17 880 ± 5 193pg/ml and HS: 24h: 6 660 ± 4 101pg/ml, 48h: 8 869 ± 3 408pg/ml, 72h: 11 
580 ± 2 933pg/ml). 
5.1.6 Cardiac function after L6 sheet transplantation (II) 
The induction of acute MI by LAD ligation effectively impaired cardiac function. HS pre-
treatment did not have the desired effect on therapy. LVEF and LVFS of the L6-SM HS pre-
treatment group decreased gradually until the end of the study, with almost the same pattern 
as the control group (Heat-Shock: 0.295 ± 0.015, 0.272 ± 0.009, 0.237 ± 0.011 and 0.145 ± 
0.008, 0.133 ± 0.005, 0.116 ± 0.005, respectively; Control: 0.297 ± 0.019, 0.264 ± 0.016, 
0.234 ± 0.017 and 0.147 ± 0.01, 0.129 ± 0.008, 0.114 ± 0.009). Surprisingly, these functional 
parameters improved in the L6-SM normal sheet group (no-shock) (0.298 ± 0.012 to 0.319 ± 
0.016 and 0.146 ± 0.007 to 0.159 ± 0.008) on the tenth day of the study but then declined 
(0.266±0.011 and 0.13±0.005) until the 28th day. The anterior wall transverse diameter in the 
diastole phase (AWTd) was significantly higher (no-shock: 0.785 ± 0.048 vs C: 0.615 ± 
0.042) on the 28th day of study versus the control group.  
- 47 - 
 
5.1.7 Histological findings: fibrosis, angiogenesis and proliferation (II) 
Fibrosis 
The LAD ligation induced severe myocardial damage and was associated with extensive left 
ventricular fibrosis. To study whether HS preconditioning combined with SM sheet therapy 
can reduce the amount of fibrotic tissue after acute MI, we assessed the percentages of 
fibrosis in histology sections. Fibrosis was evaluated from scanned images of picric acid-
stained sections. Percentage of fibrosis was calculated as picric acid-stained divided by whole 
section area. No difference between groups was detectable. No decrease occurred in fibrosis 
(controls 22.45 ± 3.168 %, no-shock: 19.76 ± 1.622%, HS: 20.38 ± 2.685%). 
Angiogenesis 
Myocardial vessel density was evaluated at the end of the study. Paraffin-embedded 
myocardial transverse sections were stained for expression of the endothelial antigen vWF as 
a marker of vascular density. There were no differences between groups in the infarct area 
(controls: 7.889 ± 2.620, No-shock: 6.417 ± 1.197, Heat-Shock: 7.250 ± 2.045). The higher 
vessel density of the non-shock group was evident (p<0.05 compared to the Heat-Shock 
group and control group) in the infarct border area, whereas the Heat-Shock group vessel 
densities remained at control level (controls: 16.41 ± 0.24, non-shock: 21.60 ± 2.62, HS: 
16.20 ± 1.01). 
Proliferation 
The ability of HS preconditioned SM cell sheet transplantation to induce cell proliferation in 
the infarcted myocardium was assessed from paraffin-embedded sections by 
immunohistochemical staining of the proliferation-associated nuclear antigen Ki67. Ki67-
positive cells were detectable only in the infarct border area. The number of proliferating 
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cells was significantly lower in the HS group when compared to controls (p<0.05, controls: 
1.000 ± 0.1925, non-shock: 0.7917 ± 0.3688, HS: 0.33330±0.1361).  
5.2 Over-expression studies 
5.2.1 Bcl-2 and VEGF over-expression in MSCs (III, IV) 
Bcl-2 expression was introduced to the MSCs with pBabepuro retroviral vector carrying the 
bcl2 gene. Bcl-2 protein expression was verified by western blotting, and was 5-fold higher in 
transfected cells than in wild-type cells. VEGF expression was introduced to the MSCs with a 
lentiviral vector carrying the human VEGF-A gene (Matsumoto et al. 2005). VEGF 
expression was verified with ELISA and was 5-fold higher than in WT cells.  
5.2.2 VEGF secretion of MSC sheets in hypoxia (III) 
To study the effect of pathological hypoxia on MSC sheet VEGF secretion, cell sheets were 
harvested and subjected to hypoxia (1% O2) for 3 days, and the growth medium from WT 
(WT) and VEGF-carrying (VEGF) sheets were collected for analysis. As a control, normal 
growth conditions were used. During the study period, VEGF expression gradually increased 
in both conditions. The amount of VEGF secretion by WT sheets remained at the same level 
during the follow-up period in both growth conditions. The results for VEGF secretion by 
WT sheets were the following: normoxia: 1 d 7105 ± 3990pg/ml, 2 d 6856 ± 3818pg/ml, 3 d 
4957 ± 1721pg/ml and hypoxia: 1 d 6379 ± 2751pg/ml, 2 d 6910 ± 3803pg/ml, 3 d 6056± 
3340pg/ml. The amount of VEGF secreted by VEGF-transfected sheets gradually increased 
in both growth conditions during the 3-day period. The results for VEGF section by VEGF-
transfected sheets were the following: normoxia: 1 d 32730 ± 10610pg/ml, 2 d 39820 ± 
11130pg/ml, 3 d 61970 ± 16140pg/ml and hypoxia: 1 d 31080 ± 9010pg/ml, 2 d 43790 ± 
8840pg/ml, 3 d 54660 ± 15760pg/ml; p<0.05 and p<0.01 compared with WT sheets in both 
growth conditions during the follow up.  
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5.2.3 Apoptosis and proliferation of mesenchymal stem cells under hypoxic 
growth conditions (III) 
We studied apoptosis- and proliferation-associated responses of MSC monolayers and sheets 
under hypoxic growth conditions. In monolayers, caspase-3 expression peaked after two days 
in WT cells and was significantly higher (p<0.01 and p<0.001) compared with VEGF cells. 
VEGF-over-expressing cells had significantly higher PCNA expression after 1 day under 
hypoxic conditions. No significant differences between WT and VEGF cells could be 
detected thereafter. In both groups, PCNA expression decreased.  
The differences in caspase-3 expression between VEGF and WT sheets were not statistically 
significant, yet there was a trend suggesting lower caspase-3 expression in VEGF sheets 
compared with WT sheets. There were no detectable differences in PCNA expression 
between the groups.  
5.2.4 Metabolic activity of gene-modified MSCs under serum deprivation 
and staurosporine treatment (IV) 
We measured the metabolic activity of mesenchymal stem cells in normal growth conditions 
and in normal growth medium (GM). The metabolic activity of Bcl-2 and VEGF over-
expressing cells was significantly higher compared to WT cells after 24 and 48 hours 
cultivation (at 24h p<0.05 Bcl-2 and VEGF compared to wt group and after 48h p< 0.01 Bc-
2l compared to WT and p<0.001 VEGF compared to WT). In normal growth medium, the 
overall proliferation was significantly higher with Bcl-2 and VEGF over-expressing MSCs 
than WT. No significant difference between Bcl-2 and VEGF groups was detected. 
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Serum deprivation 
We measured metabolic activity of MSCs after 24h and 48h of serum deprivation. The 
metabolic activity of VEGF and Bcl-2 cells was significantly higher (p<0.0001) compared to 
WT cells after 24 hours and also after 48 hours (p<0.0001 VEGF vs. WT, p<0.01 Bcl-2 vs. 
WT) and the metabolic activity of VEGF cells was significantly higher (p<0.001) compared 
to Bcl-2 over-expressing cells after 24h serum deprivation. No significant difference was 
detected between Bcl-2 and VEGF groups after 48h serum deprivation. 
Staurosporine treatment 
We measured metabolic activity of MSCs in normal growth conditions after 24h and 48h 
staurosporine treatment. The metabolic activity of Bcl-2 and VEGF over-expressing cells was 
significantly higher compared to WT cells after 24 and 48 hours cultivation (at 24h p<0.0001 
Bcl-2 and VEGF compared to WT group p<0.01 VEGF compared to Bcl-2; after 48h 
p<0.001 Bcl-2 compared to WT and p<0.01 VEGF compared to WT). No significant 
difference was detected between the Bcl-2 and VEGF groups after 48 hours staurosporine 
treatment.  
5.2.5 Cardiac performance (III) 
After a successful induction of acute MI, a significant improvement in cardiac motility was 
detected 10 days after sheet therapy in the MSC-VEGF and MSC-WT groups compared to 
control animals. Both therapy groups maintained improved cardiac performance compared 
with the control group through the 28 days of study (MSC-VEGF: EF% and FS% p≤0.001 
compared with the control group; MSC-WT: EF% and FS%: p≤0.01 and p≤0.05 compared 
with the control group and p≤0.05 MSC-VEGF compared to MSC-WT). 
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5.2.6 Histological findings: fibrosis, angiogenesis and proliferation (II) 
Fibrosis 
To study whether VEGF-MSC sheet therapy can reduce the amount of fibrotic tissue after MI 
we assessed the percentage of fibrosis in histology sections stained with picric acid. The 
VEGF group showed a significantly lower percentage of fibrosis compared with the control 
and WT groups (VEGF 22.10 ± 1.356% vs. control, p<0.001 and WT 31.21 ± 1.993%, 
p<0.01). No significant differences were seen between the WT and control groups. 
Angiogenesis 
Vascular densities were evaluated from paraffin-embedded myocardial sections stained for 
the expression of vWF. The number of vWF-positive cells was significantly higher in the 
VEGF group in both the border (control: 28.90±2.050, WT: 54.65±5.819, VEGF: 
93.38±10.58; p<0.001 VEGF compared with control, p<0.01 WT compared with control, and 
p<0.05 VEGF compared with WT), and the infarcted area (control: 8.440± 0.777, WT: 
15.14± 1.573, VEGF: 23.20± 2.974, p<0.001, VEGF and p<0.01 WT compared with control 
and p<0.05 WT compared with VEGF).  
Proliferation 
The ability of VEGF-modified MSC sheet therapy to induce cell proliferation in the infarcted 
myocardium was evaluated by proliferation-associated Ki67 antigen expression. The number 
of proliferating cells was assessed at the border (cont: 0.666±0.3333, WT: 1.83±0.7491, 
VEGF: 3.667±0.8433 and infarcted areas cont: 0.800±0.3742, WT: 1.000±0.4472, VEGF: 
3.8±0.9695) by immunohistochemical staining of the proliferation-associated nuclear antigen 
Ki67 from paraffin-embedded myocardial sections. The number of Ki67-positive cells was 
significantly higher in the VEGF group at the border and also infarct area (p <0.01 compared 
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VEGF with the control group in the border area and p<0.5 compared with the control and WT 
group in the infarct area). 
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6. DISCUSSION 
Understanding the molecular mechanisms and pathophysiology of HF followed by MI has 
increased during recent decades. Current medications have decreased mortality but neither 
medical nor surgical treatments are able to cure the underlying cause of MI-induced HF. The 
last treatment option is still heart transplantation. During recent years, cell-based 
transplantation research has expanded remarkably (David et al. 2010). The strategies to 
transplant new contractile cells into the infracted myocardium to replace and re-build the 
damaged tissue have been under intense research for two decades now. Several different cell 
types from various sources have been studied in experimental and clinical studies (Malliaras 
& Marbán 2011). 
 
Among the cells investigated, SMs have been most studied. However, the first large 
randomised clinical study (MAGIC) showed a high number of arrhythmic events in the SM-
treated patients and no improvement in the primary end points. This brought basic monolayer 
SM cell injection therapy to an end (Menasché et al. 2008). Also, MSCs have been the focus 
of clinical and experimental investigations for the repair of damaged myocardium due to their 
immunomodulatory properties and multi-lineage differentiation capacity (Uccelli et al. 2006; 
Krampera et al. 2003; Le Blanc et al. 2004; Toma et al. 2002; Jiang et al. 2002; Nagaya et al. 
2005). Several animal models and clinical trials have shown the therapeutic effect of MSCs 
after myocardial infarction trials (Nayan et al. 2011; Miyahara et al. 2006).  
 
MSC and SM therapies are usually carried out by invasive methods (intracoronary infusions 
or intramyocardial injections), which can cause tissue damage, introduce arrhythmia, and 
enhance dissociation-induced cell death (Shabbir et al. 2009; Hamdi et al. 2011). After 
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transplantation, cells face oxygen- and nutrition-deprived target tissue conditions which also 
compromise the effect of the therapy. Preconditioning of cells prior to transplantation has 
been shown to enhance the cell survival and duration of the therapy. In this study we 
investigated HS preconditioning combined with SMs, as well as gene over-expression 
combined with MSC therapy. To overcome problems associated with invasive cell delivery 
methods we used self-aggregating scaffoldless cell sheets as the means to transplant cells into 
the heart after myocardial infarction. 
 
6.1 Heat Shock Studies 
HS, due to its non-viral nature and straightforward usefulness, has been suggested as a 
method of choice in cell preconditioning prior transplantation (Suzuki et al. 2000). By 
inducing the expression of chaperone proteins which preserve the three-dimensional 
functional structures of critical proteins upon stress, HS could provide an efficient and 
relatively easy pre-transplantation procedure for enhancing SM therapy (Beere 2004; Mosser 
et al. 1997).  
We first evaluated the usefulness of HS pre-treatment and the induction of HS proteins for 
improving SM differentiation under hypoxia and the effect of HS preconditioning in SM cell 
sheets both in vitro and eventually in ischaemic heart failure in vivo. The expression of 
troponin T, a differentiation-associated muscle-specific protein, was used as a marker of the 
myogenic program. Troponin T is a member of the troponin complex that mediates calcium-
induced muscle contractions (Farah & Reinach 1995). The myogenic differentiation program 
is constituted by extracellular cues activating cascades of events driving SM differentiation 
(Bryson-Richardson & Currie 2008). Proteolytic enzymes need to be activated for SM fusion. 
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Pro-apoptotic caspase-3 has been identified to be involved in SM differentiation (Fernando et 
al. 2002). This finding links the apoptotic cascades and differentiation within the 
differentiated cells. Our results using caspase-3 inhibition on HS preconditioned cells under 
hypoxia showed that the increased expression of troponin due to HS persisted in cells treated 
with Z-DEVD-FMK. This suggested that HS may reduce dependence of differentiation on 
caspase-3.  
In many ways, SM transplantation therapy could assist in the restoration of infarcted tissue 
functions. In order to fulfil all possible actions SMs must retain their viability and 
functionality. These parameters can be evaluated in terms of maintaining the cells’ ability to 
differentiate. We showed that the functionality of the SMs and their capacity to respond to 
external stimuli, in terms of differentiation, is sustained under hypoxia by HS pre-treatment 
associated with preserved troponin T expression and myotube formation. This preserved 
functionality may contribute to enhanced paracrine effects, since SM differentiation is known 
to enhance cytokine and growth factor production (Baeza-Raja & Muñoz-Cánoves  2004; 
Yoshiko et al. 2002). 
Clinical results from SM injection therapy have shown severe arrhythmias; therefore new SM 
administration techniques are needed. We examined the usefulness of HS preconditioning 
using in vivo SM sheet therapy. Despite the high expectations, the most valuable result 
contradicted findings from previous studies. HS showed no beneficial effects on SM sheet 
therapy in an AMI rat model. In fact, it deteriorated the therapeutic effect of L6 myoblast 
sheets. We found decreased expression of VEGF in the HS pre-treated sheets and, 
furthermore, the therapeutic effect of these sheets disappeared in an acute heart failure model 
with less vascular structures in the infarct border area. HS has a cell-protective effect in early 
stages after preconditioning, but hypoxic conditions also weaken HSP70/72 expression 72 
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hours after the HS. Eventually, the HS-preconditioned sheets lack the myocardium-protective 
function seen in non-conditioned SM sheets. 
 
6.2 Gene overexpression studies 
Ex vivo genetic modification of transplanted cells has shown great promise in heart cell 
therapy (Li et al. 2007; Kode et al. 2009; Griffin et al. 2010). Prior studies have shown that 
Bcl-2 and VEGF expression can protect transplanted cells in heart cell therapy and enhance 
the therapeutic effect (Kitabayashi et al. 2010; Li et al. 2007; Dai et al. 2007).  
We studied proliferation- and apoptosis-associated responses of VEGF–over-expressing 
mesenchymal stem cell monolayers versus sheets in hypoxic in vitro conditions. Also, the 
ability of proangiogenic VEGF in MSCs to functionally enhance cell sheet transplantation in 
a rat model of AMI and metabolic responses of VEGF and anti-apoptotic Bcl-2 gene over-
expressing MSCs under different stress conditions was studied. A methodological weakness 
of these studies might be the control group, which received non-transducted cells. A more 
suitable control group would have been cells transducted with an empty vector, when the 
efficacy of the gene expression is evaluated. 
These studies showed that VEGF expression improves the MSC sheet cell transplantation 
therapy in vivo, and that cells over-expressing VEGF have an increased tolerance for 
hypoxia-induced apoptosis in vitro.  
In hypoxia, VEGF regulation takes place at both the transcriptional and post-transcriptional 
levels. Under hypoxic conditions, the short half-life of VEGF mRNA is extended (Stein et al. 
1998). This study did not find an increase in WT sheet VEGF secretion under hypoxic 
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conditions. This finding suggests that the three-dimensional structure of the sheets might be 
able to protect cells from hypoxia. In cell sheets, the cell-cell connections are preserved and 
therefore the cell signalling cascades can also function differently compared with cell 
suspensions.  
The metabolic activity and survival of transplanted cells are essential factors for successful 
cell therapy. The mechanisms of cell death in infarction areas of the myocardium are 
dependent on the location of cells in relation to the blocked artery. In infarct core areas 
necrosis is predominant, whereas programmed cell death by apoptosis is more important in 
the border areas where there is some collateral blood flow left (Krijnen et al. 2002). The 
limited supply of oxygen and nutrients elicits cell death responses, such as the generation of 
reactive oxygen species and the targeting of mitochondrial function (Krijnen et al. 2002; 
Regula et al. 2003).  
We experimentally imitated these severe target tissue conditions in vitro by removing serum 
from the culture, thus depriving cells of nutrients and growth factors, whilst treating cells 
with staurosporine to induce apoptosis resembling the infarcted myocardium (Gil et al. 2003).  
We found that the overall metabolic activity of cells in normal cell growth conditions and in 
normal growth medium were significantly higher in gene-modified cells than in WT cells and 
that the metabolic activity of VEGF-over-expressing cells was higher than Bcl-2-modified 
cells. Moreover, we showed that the introduction of VEGF expression in MSCs enhances 
metabolic activity during serum starvation and staurosporine treatment when compared to the 
Bcl-2-expressing and WT MSCs. Both Bcl-2 and VEGF over-expression protected cells 
against nutrient deprivation and staurosporine-induced apoptosis when compared to untreated 
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WT cells. Surprisingly, however, VEGF-modified cells were found to be more resistant to 
these stressful in vitro conditions.  
These results and previous studies suggest that VEGF over-expression in MSCs may enhance 
their therapeutic potential in vitro but also in vivo by improving and sustaining the metabolic 
activity. In addition, these results provide insight into how a proangiogenic strategy may have 
a more beneficial therapeutic effect than an anti-apoptotic strategy in mesenchymal stem cell 
therapy.  
6.3 Future directions 
 
Cell preconditioning methods have been shown to improve resistance to oxidative stress, and 
to increase cell differentiation potency and also the paracrine activity of transplanted cells in 
harsh target tissue conditions. However, which method has the greatest benefits and lowest 
risks when clinical applications are considered still seems to be unclear.  
Both animal studies and clinical experiments have provided solid evidence that various cell 
types can beneficially affect myocardial perfusion and contractile performance after 
myocardial tissue damage. Despite extensive efforts, however, there are still many questions 
waiting to be solved. The precise mechanisms by which the therapeutic cells improve cardiac 
performance should be further studied and more insight in procedural issues and therapeutic 
approaches is needed. For example, the phenomenon of transdifferentiation, by which 
differentiated cells can change fate and become another differentiated cell type, may serve as 
a mechanism to obtain an abundant number of cells required for transplantation. This is valid 
also in adult stem cells. They are committed to a developmental programme; however they 
can switch into a cell type of a different lineage by genetic reprogramming (Song and Tuan, 
2004). This plasticity is exemplified by the ability of MSCs to differentiate into directions 
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that are not typical mesenchymal derivatives.  However, great effort is still needed to 
generate a method for the long-lasting differentiation of cell types with therapeutic value. 
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7. SUMMARY AND CONCLUSIONS 
 
The present study evaluated HS preconditioning of SM as well as VEGF and Bcl-2 over-
expressing MSCs in terms of their therapeutic capacity in vitro and in vivo in the treatment of 
acute myocardial infarction. The main findings of these studies are the following: 
 
I  HS preconditioning leads to increased expression of SM differentiation-
associated troponin, and to a reduction of caspase-3 activity under hypoxic 
conditions.  
II  HS protects SM sheets from hypoxia-associated apoptosis in vitro, but reduces 
VEGF expression of the sheet, leading to a lower therapeutic effect in heart 
failure.  
III  MSC sheets carrying VEGF enhance cell sheet transplantation therapy for acute 
myocardial infarction. 
IV  VEGF over-expression in MSCs may enhance their therapeutic potential by 
improving their metabolic activity. Pro-angiogenic strategies may have more 
therapeutic benefits than anti-apoptotic strategies in MSC therapy.  
 
These results provide evidence that cell preconditioning has a significant impact on cell 
behaviour both in vitro and in vivo. HS protects cells in vitro against oxidative stress but does 
not offer any therapeutic efficacy for in vivo cell sheet therapy. A proangiogenic VEGF 
strategy combined with cell sheet enhances their therapeutic efficacy for treating HF after 
acute myocardial infarction and may be a more beneficial application when compared to an 
anti-apoptotic strategy. 
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